[go: up one dir, main page]

WO2002046224A3 - Compositions and methods relating to lung specific genes and proteins - Google Patents

Compositions and methods relating to lung specific genes and proteins Download PDF

Info

Publication number
WO2002046224A3
WO2002046224A3 PCT/US2001/050687 US0150687W WO0246224A3 WO 2002046224 A3 WO2002046224 A3 WO 2002046224A3 US 0150687 W US0150687 W US 0150687W WO 0246224 A3 WO0246224 A3 WO 0246224A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
compositions
lung
antagonists
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/050687
Other languages
French (fr)
Other versions
WO2002046224A2 (en
Inventor
Herve Recipon
Yongming Sun
Sei-Yu Chen
Chenghua Liu
Leah R Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Priority to AU2002241730A priority Critical patent/AU2002241730A1/en
Priority to JP2002547960A priority patent/JP2004520821A/en
Priority to EP01988422A priority patent/EP1355934A2/en
Publication of WO2002046224A2 publication Critical patent/WO2002046224A2/en
Anticipated expiration legal-status Critical
Publication of WO2002046224A3 publication Critical patent/WO2002046224A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to nucleic acids and polypeptides present in normal and neoplastic lung cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-cancerous disease states in lung, identifying lung tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered lung tissue for treatment and research.
PCT/US2001/050687 2000-10-26 2001-10-26 Compositions and methods relating to lung specific genes and proteins Ceased WO2002046224A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002241730A AU2002241730A1 (en) 2000-10-26 2001-10-26 Compositions and methods relating to lung specific genes and proteins
JP2002547960A JP2004520821A (en) 2000-10-26 2001-10-26 Compositions and methods for lung-specific genes and proteins
EP01988422A EP1355934A2 (en) 2000-10-26 2001-10-26 Compositions and methods relating to lung specific genes and proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24346100P 2000-10-26 2000-10-26
US60/243,461 2000-10-26
US25205500P 2000-11-20 2000-11-20
US60/252,055 2000-11-20
US25249600P 2000-11-22 2000-11-22
US60/252,496 2000-11-22

Publications (2)

Publication Number Publication Date
WO2002046224A2 WO2002046224A2 (en) 2002-06-13
WO2002046224A3 true WO2002046224A3 (en) 2003-08-21

Family

ID=27399666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050687 Ceased WO2002046224A2 (en) 2000-10-26 2001-10-26 Compositions and methods relating to lung specific genes and proteins

Country Status (4)

Country Link
EP (1) EP1355934A2 (en)
JP (1) JP2004520821A (en)
AU (1) AU2002241730A1 (en)
WO (1) WO2002046224A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
DE10254601A1 (en) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
CA2890438C (en) 2012-11-13 2022-10-18 Biontech Ag Agents for treatment of claudin expressing cancer diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008206A1 (en) * 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
WO2001066751A2 (en) * 2000-03-08 2001-09-13 Pharmacia & Upjohn Company G protein-coupled receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008206A1 (en) * 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
WO2001066751A2 (en) * 2000-03-08 2001-09-13 Pharmacia & Upjohn Company G protein-coupled receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 10 April 1999 (1999-04-10), BATES, K.: "Human DNA sequence from clone RP1-231N13 on chromosome 6q22 contains GSSs", XP002231917, retrieved from EBI Database accession no. AL049613 *
DATABASE EMBL [online] 4 September 1998 (1998-09-04), ADAMS MD ET AL.: "CIT-HSP-2379F9.TR CIT-HSP Homo sapiens genomic clone 2379F9, genomic survey sequence", XP002231918, retrieved from EBI Database accession no. AQ111660 *
DATABASE GENBANK [online] 6 November 1998 (1998-11-06), GARDNER ET AL.: "Ser/Thr protein kinase (Plasmodium falciparum)", XP002231919, retrieved from NCBI Database accession no. AAC71910 (gi:3845228) *

Also Published As

Publication number Publication date
JP2004520821A (en) 2004-07-15
AU2002241730A1 (en) 2002-06-18
WO2002046224A2 (en) 2002-06-13
EP1355934A2 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
WO2002062945A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002040672A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002055735A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2002064741A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002077232A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002042463A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2002088375A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002068645A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002042776A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2002039431A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2002046224A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002048370A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2002077234A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2002066605A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002042460A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002068633A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002036616A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2003020953A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2002042329A3 (en) Compositions and methods relating to prostate specific genes and proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002547960

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001988422

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001988422

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001988422

Country of ref document: EP